Trafalgar International (GCAN) Receivables - Other (2019 - 2020)
Trafalgar International (GCAN) posted Receivables - Other of $28000.0 for Q1 2020, little changed on a QoQ basis from $28000.0 in Q4 2019.
Analysis
Trafalgar International (GCAN) Receivables - Other (2019 - 2020) Analysis & Trends
Trafalgar International has reported Receivables - Other for 2 years, with the latest figure at $28000.0 in Q1 2020.
- On a quarterly basis, Receivables - Other changed N/A year-over-year to $28000.0 in Q1 2020; TTM through Mar 2020 was $28000.0, a N/A change from a year earlier, with the FY2019 full-year figure at $28000.0, changed N/A from the prior year.
- Receivables - Other was $28000.0 for Q1 2020 at Trafalgar International, roughly flat from $28000.0 in the prior quarter.
- The five-year high for Receivables - Other was $28000.0 in Q4 2019, with the low at $28000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - |